BI 765250
Alternative Names: BI-765250Latest Information Update: 28 Mar 2023
At a glance
- Originator Boehringer Ingelheim
- Class Antipsoriatics; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Plaque psoriasis
Most Recent Events
- 09 Mar 2023 Phase-I clinical trials in Plaque psoriasis (In adults, In the elderly) in Bulgaria (IV) (NCT05728489)
- 09 Mar 2023 Phase-I clinical trials in Plaque psoriasis (In adults, In the elderly) in Bulgaria (SC) (NCT05728489)
- 20 Feb 2023 Boehringer Ingelheim plans a phase I trial for plaque Psoriasis for low, medium and high dose (NCT05728489)